Blog - QualityStocks

WednesdayJun 24, 2026 11:15 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline

VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing. The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026. VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”), and other antibody-based formats. VERAXA recently began trading on the NASDAQ Capital Market under the…

WednesdayJun 24, 2026 10:50 am

QualityStocksNewsBreaks – Greenland Energy Company (NASDAQ: GLND) Advances Jameson Land Basin Toward Exploration Drilling

Robert Price, CEO of Greenland Energy Company Energy, Oil & Gas Magazine profiles CEO Robert Price as company prepares for October 2026 exploration campaign in East Greenland Greenland Energy (NASDAQ: GLND) is advancing development of the Jameson Land Basin in East Greenland, an onshore petroleum basin that CEO Robert Price described as one of the world's last largely undrilled frontier oil regions. In an interview with Energy, Oil & Gas Magazine, Price said the company holds rights to up to a 70% interest in the basin and is leveraging extensive seismic data originally collected by Atlantic Richfield Company ("ARCO") during…

WednesdayJun 24, 2026 10:30 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Cancer Nanomedicine Enters a New Generation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. Cancer nanomedicine is emerging from an early period of skepticism, with more than 20 approved formulations now improving therapeutic index and patient quality of life during treatment Onco-Innovations' lead drug candidate, ONC010, pairs a small-molecule PNKP inhibitor with a polymer nanodelivery system designed to extend circulation, increase drug retention in tumor, and improve tolerability Recent manufacturing updates, including kilogram-scale precursor production and a proposed Nanosoft Polymers collaboration, point to a sharpening focus on scalability, reproducibility, and regulatory readiness ahead of first-in-human studies For decades,…

WednesdayJun 24, 2026 10:25 am

QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Terminates Proposed FST Acquisition, Refocuses on Internal Security Technology Development

Massimo Group (NASDAQ: MAMO), a manufacturer and distributor of powersports vehicles and mobility solutions, announced it has terminated its previously proposed acquisition of FST Development Company Limited. The company said that after reviewing its strategic priorities, capital allocation plans and recent development progress, it elected not to proceed with the transaction or the previously contemplated stock-based acquisition structure. Massimo said recent advancements in its internal development programs and strategic partnerships have strengthened its position in intelligent patrol systems, autonomous patrol vehicles, drone-assisted security technologies and AI-powered monitoring platforms, reducing the need for external acquisitions. To support these initiatives, the company’s controlling shareholder has committed up to $4 million in funding to accelerate…

WednesdayJun 24, 2026 9:50 am

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing Lucid-MS, a patented first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis (“MS”), according to an AINewsWire editorial. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound intended to prevent myelin degradation. The company recently filed an Investigational New Drug application with the U.S. Food and Drug Administration and is preparing for a phase 2 clinical trial following successful completion of phase 1 safety…

WednesdayJun 24, 2026 9:45 am

Beeline Holdings Inc. (NASDAQ: BLNE) Joins Russell Microcap Index as Digital Mortgage Platform Expands AI and Equity Strategy

Beeline’s AI-enabled underwriting and customer acquisition tools are designed to reduce friction in mortgage approvals, particularly for gig-economy borrowers. Shares of Beeline Holdings, Inc. are set to join the Russell Microcap Index effective June 29, increasing visibility among institutional investors. The company’s first-quarter 2026 revenue more than doubled year over year to $2.7 million, while loan originations rose to $85.6 million. Management is targeting younger real estate investors alongside older homeowners seeking access to home equity without refinancing. The company continues investing in automation and adjacent software capabilities as it pursues a broader housing finance technology strategy. Beeline Holdings (NASDAQ:…

WednesdayJun 24, 2026 9:40 am

QualityStocksNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians

Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD(TM) and PrecisionCHD(TM) tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning. Cardio Diagnostics said Epi+Gen CHD(TM) evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD(TM) helps diagnose coronary heart disease and identify its underlying molecular drivers. The company…

WednesdayJun 24, 2026 9:20 am

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Engages Nanosoft to Advance ONC010 Development Program

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced a services agreement with Nanosoft Polymers to support development of ONC010, the company’s lead nanoparticle-formulated PNKP inhibitor. Under the agreement, Nanosoft will provide polymer process development, analytical characterization, formulation optimization, scale-up support and technology transfer services for Onco’s proprietary PEO-PBCL polymer platform as the program advances through IND-enabling development and preparation for future clinical studies. The collaboration is intended to strengthen the manufacturing and formulation foundation of ONC010 by establishing scalable polymer production processes, enhancing analytical methods and…

WednesdayJun 24, 2026 9:00 am

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline

VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded its laboratory footprint at its existing research and development site in Heidelberg, Germany, under a previously executed long-term lease agreement. The additional space will support planned growth of the company’s R&D team, installation of new laboratory equipment and completion of infrastructure needed to advance future development activities. VERAXA said the expansion aligns with efforts to advance its growing portfolio of proprietary and partnered oncology programs from discovery-stage research toward early clinical development. The company’s pipeline is centered on its BiTAC platform, including BiTAC-TCE and BiTAC-ADC…

WednesdayJun 24, 2026 9:00 am

Greenland Mines Ltd. (NASDAQ: GRML) Is ‘One to Watch’

Greenland Mines’ flagship Skaergaard Project hosts an NI 43-101 Mineral Resource estimate containing 11.4 million ounces PdEq in the Indicated category and 14.1 million ounces PdEq in the Inferred category. The pending acquisition of the Sarfartoq Project would add an advanced rare earth asset with a historical resource estimate, extensive drilling history and exposure to magnet rare earth elements including neodymium and praseodymium. The company’s relationship with Neo Performance Materials includes an offtake arrangement covering up to 60% of future Sarfartoq production, subject to completion of the acquisition and future project development. Greenland Mines is pursuing a North Atlantic critical…

Site Search

Company Search